Ohio Innovation Fund — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.
BiotechDigital HealthMedical DevicesColumbus, US
Robert Shalwitz(Executive Officer, Director)inRachael Wingo(Executive Officer)
BoardWayne Embree(Director)Tim Willis(Director)Bethany George(Director)in
Board seatFaith Voinovich· per SEC Form D
Co-investorsCincyTechJobsOhio VenturesJumpstart VenturesRev1 Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.